IP Group Valuation
Is IPOL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IPOL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IPOL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IPOL's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IPOL?
Key metric: As IPOL is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
What is IPOL's PB Ratio? | |
---|---|
PB Ratio | 0.4x |
Book | UK£1.09b |
Market Cap | UK£426.49m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | -1.9x |
Enterprise Value/EBITDA | -1.7x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does IPOL's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.6x | ||
GROW Molten Ventures | 0.5x | 91.3% | UK£594.5m |
ARIX Arix Bioscience | 0.7x | n/a | UK£176.5m |
ORIT Octopus Renewables Infrastructure Trust | 0.7x | n/a | UK£399.8m |
SIHL Symphony International Holdings | 0.4x | n/a | US$156.1m |
IPOL IP Group | 0.4x | 139.0% | UK£426.5m |
Price-To-Book vs Peers: IPOL is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.6x).
Price to Book Ratio vs Industry
How does IPOL's PB Ratio compare vs other companies in the GB Capital Markets Industry?
Price-To-Book vs Industry: IPOL is good value based on its Price-To-Book Ratio (0.4x) compared to the UK Capital Markets industry average (0.9x).
Price to Book Ratio vs Fair Ratio
What is IPOL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 0.4x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate IPOL's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | UK£0.43 | UK£1.13 +160.1% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
Nov ’25 | UK£0.46 | UK£1.13 +146.7% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
Oct ’25 | UK£0.50 | UK£1.13 +127.1% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
Sep ’25 | UK£0.42 | UK£1.13 +168.7% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
Aug ’25 | UK£0.43 | UK£1.13 +164.0% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
Jul ’25 | UK£0.43 | UK£1.13 +164.3% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
Jun ’25 | UK£0.54 | UK£1.13 +107.7% | 11.5% | UK£1.26 | UK£1.00 | n/a | 2 |
May ’25 | UK£0.47 | UK£1.28 +170.6% | 1.6% | UK£1.30 | UK£1.26 | n/a | 2 |
Apr ’25 | UK£0.48 | UK£1.28 +168.2% | 1.6% | UK£1.30 | UK£1.26 | n/a | 2 |
Mar ’25 | UK£0.49 | UK£1.32 +168.4% | 1.1% | UK£1.33 | UK£1.30 | n/a | 2 |
Feb ’25 | UK£0.53 | UK£1.32 +148.6% | 1.1% | UK£1.33 | UK£1.30 | n/a | 2 |
Jan ’25 | UK£0.58 | UK£1.32 +126.7% | 1.1% | UK£1.33 | UK£1.30 | n/a | 2 |
Dec ’24 | UK£0.51 | UK£1.32 +160.4% | 1.1% | UK£1.33 | UK£1.30 | n/a | 2 |
Nov ’24 | UK£0.44 | UK£1.32 +195.8% | 1.1% | UK£1.33 | UK£1.30 | UK£0.46 | 2 |
Oct ’24 | UK£0.53 | UK£1.18 +122.9% | 16.7% | UK£1.33 | UK£0.90 | UK£0.50 | 3 |
Sep ’24 | UK£0.58 | UK£1.18 +102.2% | 16.7% | UK£1.33 | UK£0.90 | UK£0.42 | 3 |
Aug ’24 | UK£0.60 | UK£1.18 +95.8% | 16.7% | UK£1.33 | UK£0.90 | UK£0.43 | 3 |
Jul ’24 | UK£0.57 | UK£1.18 +106.8% | 16.7% | UK£1.33 | UK£0.90 | UK£0.43 | 3 |
Jun ’24 | UK£0.56 | UK£1.22 +120.0% | 19.5% | UK£1.47 | UK£0.90 | UK£0.54 | 3 |
May ’24 | UK£0.56 | UK£1.22 +118.1% | 19.5% | UK£1.47 | UK£0.90 | UK£0.47 | 3 |
Apr ’24 | UK£0.55 | UK£1.22 +121.0% | 19.5% | UK£1.47 | UK£0.90 | UK£0.48 | 3 |
Mar ’24 | UK£0.66 | UK£1.29 +96.0% | 11.7% | UK£1.47 | UK£1.10 | UK£0.49 | 3 |
Feb ’24 | UK£0.61 | UK£1.29 +110.4% | 11.7% | UK£1.47 | UK£1.10 | UK£0.53 | 3 |
Jan ’24 | UK£0.56 | UK£1.29 +130.4% | 11.7% | UK£1.47 | UK£1.10 | UK£0.58 | 3 |
Dec ’23 | UK£0.67 | UK£1.32 +97.5% | 12.0% | UK£1.47 | UK£1.10 | UK£0.51 | 3 |
Nov ’23 | UK£0.63 | UK£1.32 +110.9% | 12.0% | UK£1.47 | UK£1.10 | UK£0.44 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
ASA International Group
UK£64.8m
Provides microfinancing services in Africa and Asia.
ASAI
UK£0.65
7D
1.6%
1Y
48.5%
HAL Trust
€10.4b
Operates through multi-sectors in Europe, the United States, Canada, Asia, and internationally.
0K9V
€115.80
7D
1.6%
1Y
1.6%
Man Group
UK£2.4b
Man Group Limited is a publicly owned investment manager.
EMGL
UK£2.11
7D
0.1%
1Y
-2.5%